N/A N=122 Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
Neurofibromatosis 1 · Chronic Pain
Primary: Engagement Activity — 4.7; 8.1 minutes per day
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=4 Fluoxetine Treatment of Depression in Down Syndrome
Down Syndrome · Depression
Primary: Proportion of Participants Who Responded to Treatment at 16 Weeks According to Improvement Item of the Clinical Global Impression-Scale (Response Defined as CGI-I=1 or…
Phase 1 N=12 A Study in Healthy Men to Test How BI 1358894 is Taken up in the Body and How Food Influences the Amount of BI 1358894 in the Blood
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of BI 1358894 Over the Time Interval From 0 to Infinity After i.v. Administration and After Oral Administration…
Phase 3 N=1,426 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster
Herpes Zoster
Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 4.1 Cases per 1000 person-years
N/A N=913 Human-centered Design and Communities of Practice to Improve Home-based Tuberculosis Contact Investigation in Uganda
Tuberculosis · Tuberculosis, Pulmonary
Primary: Completion of TB Evaluation — 266; 1144 Participants — p=<0.001
N/A N=253 Lifestyle Physical Activity and Cognitive Training Interventions
Cognitive Decline · Cardiovascular Diseases · Cognitive Dysfunction
Primary: Change in East Boston Memory Test Scores From Baseline to 24 Weeks, 48 Weeks, and 72 Weeks — 0.03; -0.02; 0.01; 0.05 score on a scale — p=.409
Phase 1 N=44 A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by Protocol Definition of AE — 3; 0; 0; 1 Participants
N/A N=281 Examining Racial and SocioEconomic Disparities (ERASED) in Chronic Low Back Pain Study
Back Pain Lower Back Chronic
Primary: Average Clinical Pain Severity — 5.1; 3.9 units on a scale
Phase 2 N=82 Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Prostate Carcinoma
Primary: Change in Weekly Patient-reported Hot Flash Scores — -9.94; -13.95; -4.85 units on a scale — p=0.0019
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 3 N=26 An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Generalized Myasthenia Gravis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Over the Main Treatment Period — 73.1 percentage of participants
N/A N=60 Assessing Sleep in Blackfeet Families With K-3rd Grade Children
Sleep
Primary: Sleep Trouble — 1.32 Scores on a scale
Phase 4 N=199 The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients
Spine Fusion · Pain, Postoperative · Opioid Use
Primary: Average Postoperative Pain Score - PACU/ Post-anesthesia Care Unit — 3.22; 5.66; 5.05 Pain score NSR
Phase 3 N=355 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Renal Failure · End Stage Renal Disease · Hemodialysis
Primary: Number of Participants With Loss of Secondary Patency — 29; 34 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day